External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Morote, Juan
• dc.contributor.author Borque-Fernando, Ángel
• dc.contributor.author Esteban, Luis M.
• dc.contributor.author Picola, Natàlia
• dc.contributor.author Muñoz-Rodríguez, Jesús
• dc.contributor.author Paesano, Nahuel
• dc.contributor.author Ruiz Plazas, Xavier
• dc.contributor.author Muñoz-Rivero, Marta V.
• dc.contributor.author Celma, Anna
• dc.contributor.author García de Manuel, Gemma
• dc.contributor.author Miró, Berta
• dc.contributor.author Abascal-Junquera, José María
• dc.contributor.author Servian, Pol
• dc.date.accessioned 2025-07-22T06:48:18Z
• dc.date.available 2025-07-22T06:48:18Z
• dc.date.issued 2024
• dc.description.abstract Purpose: To validate the Barcelona-magnetic resonance imaging predictive model (BCN-MRI PM) for clinically significant prostate cancer (csPCa) in Catalonia, a Spanish region with 7.9 million inhabitants. Additionally, the BCN-MRI PM is validated in men receiving 5-alpha reductase inhibitors (5-ARI). Materials and methods: A population of 2,212 men with prostate-specific antigen serum level > 3.0 ng/ml and/or a suspicious digital rectal examination who underwent multiparametric MRI and targeted and/or systematic biopsies in the year 2022, at ten participant centers of the Catalonian csPCa early detection program, were selected. 120 individuals (5.7%) were identified as receiving 5-ARI treatment for longer than a year. The risk of csPCa was retrospectively assessed with the Barcelona-risk calculator 2 (BCN-RC 2). Men undergoing 5-ARI treatment for less than a year were excluded. CsPCa was defined when the grade group was ≥ 2. Results: The area under the curve of the BCN-MRI PM in 5-ARI naïve men was 0.824 (95% CI 0.783-0.842) and 0.849 (0.806-0.916) in those receiving 5-ARI treatment, p 0.475. Specificities at 100, 97.5, and 95% sensitivity thresholds were to 2.7, 29.3, and 39% in 5-ARI naïve men, while 43.5, 46.4, and 47.8%, respectively in 5-ARI users. The application of BCN-MRI PM would result in a reduction of 23.8% of prostate biopsies missing 5% of csPCa in 5-ARI naïve men, while reducing 25% of prostate biopsies without missing csPCa in 5-ARI users. Conclusions: The BCN-MRI PM has achieved successful validation in Catalonia and, notably, for the first time, in men undergoing 5-ARI treatment.
• dc.format.mimetype application/pdf
• dc.identifier.citation Morote J, Borque-Fernando Á, Esteban LM, Picola N, Muñoz-Rodriguez J, Paesano N, et al. External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors. World J Urol. 2024 Jul 10;42(1):393. DOI: 10.1007/s00345-024-05092-0
• dc.identifier.doi http://dx.doi.org/10.1007/s00345-024-05092-0
• dc.identifier.issn 0724-4983
• dc.identifier.uri http://hdl.handle.net/10230/70961
• dc.language.iso eng
• dc.publisher Springer
• dc.relation.ispartof World J Urol. 2024 Jul 10;42(1):393
• dc.rights © The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword 5-alpha reductase inhibitor
• dc.subject.keyword Predictive model
• dc.subject.keyword Risk calculator
• dc.subject.keyword Significant prostate cancer
• dc.subject.keyword Validation
• dc.title External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion